China charges former AstraZeneca executive – what it means for global pharmaceutical firms



AstraZeneca’s former China head has been formally charged with medical insurance fraud, illegal trading and unlawful collection of personal information, more than a year after he first came under investigation – casting a shadow over the Swedish-British drug maker’s expansion in its second-largest market.

The pharmaceutical giant confirmed to the Financial Times and Reuters that Leon Wang was one of two individuals indicted, as referenced in its latest earnings report published on Tuesday. The company did not name him in the report, stating only that a former executive vice-president and “senior employee” had been charged.

AstraZeneca also said it was not alleged to have received any illegal gains from Wang’s offences.

The company did not respond to a request for comment from the South China Morning Post.

The case, reminiscent of the 2013 GlaxoSmithKline bribery scandal, underscores broader regulatory shifts in the country’s healthcare sector and foreign investment landscape. China is the world’s second-largest pharmaceutical market, driven by an ageing population and rising healthcare spending.
The charges come as AstraZeneca deepens its commitment to the Chinese market. In January, it announced plans to invest US$15 billion in the country through 2030 to expand pharmaceutical manufacturing and research and development (R&D).
  • Related Posts

    India-US trade portal attracts 31,000 visitors, registers 2,500 exporters and importers in three months

    The portal has listed over 4,000 products since its launch, with Indian Ambassador Vinay Kwatra saying it will boost business partnerships and help achieve the $500-billion bilateral trade target by…

    Continue reading
    BOJ governor says Japan inflation near 2% target, signals scope for more rate hikes

    Bank of Japan Governor Kazuo Ueda says underlying inflation is approaching the central bank’s 2% target, citing strong AI-driven investment, rising export demand and a tight labour market. Markets expect…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *